Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice

Nature Communications

Volumn 5, Issue , 2014, Pages

  Bogorad, Roman L ^a   Yin, Hao ^a   Zeigerer, Anja ^b   Nonaka, Hidenori ^b   Ruda, Vera M ^a   Zerial, Marino ^b   Anderson, Daniel G ^a,c,d   Koteliansky, Victor ^a,e  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^e SKOLKOVO INSTITUTE OF SCIENCE AND TECHNOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; BETA CATENIN; BETA1 INTEGRIN; INTEGRIN; INTEGRIN RECEPTOR; MESSENGER RNA; NANOPARTICLE; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; ALPHA INTEGRIN; BETA INTEGRIN;

CANCER; GENE EXPRESSION; INHIBITION; MORPHOLOGY; PARTICLE SIZE; RNA; RODENT; TUMOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL MATURATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DRUG FORMULATION; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; LIVER; LIVER CELL; LIVER CELL CARCINOMA; MORPHOLOGY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; ONCOGENE; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; TUMOR CELL; ANIMAL; DISEASE COURSE; DOWN REGULATION; EXPERIMENTAL LIVER NEOPLASM; GENETICS; METABOLISM;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE PROGRESSION; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTES; INTEGRIN ALPHA CHAINS; INTEGRIN BETA CHAINS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; NANOPARTICLES; PROTO-ONCOGENE PROTEINS C-MET; RNA, SMALL INTERFERING;

EID: 84901357792     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4869     Document Type: Article

References (58)

1. Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687 (2002). (Pubitemid 35283958)
2. Brakebusch, C. & Fässler, R. Beta 1 integrin function in vivo: adhesion, migration and more. Cancer Metastasis Rev. 24, 403-411 (2005). (Pubitemid 41569980)
3. Fässler, R. & Meyer, M. Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev. 9, 1896-1908 (1995).
4. Stephens, L. E. et al. Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. Genes Dev. 9, 1883-1895 (1995).
5. Aumailley, M., Pesch, M., Tunggal, L., Gaill, F. & Fässler, R. Altered synthesis of laminin 1 and absence of basement membrane component deposition in (beta) 1 integrin-deficient embryoid bodies. J. Cell Sci. 113(Pt 2), 259-268 (2000). (Pubitemid 30088971)
6. Li, S. et al. Matrix assembly, regulation, and survival functions of laminin and its receptors in embryonic stem cell differentiation. J. Cell Biol. 157, 1279-1290 (2002). (Pubitemid 34847796)
7. Aszodi, A., Hunziker, E. B., Brakebusch, C. & Fässler, R. Beta1 integrins regulate chondrocyte rotation, G1 progression, and cytokinesis. Genes Dev. 17, 2465-2479 (2003). (Pubitemid 37214793)
8. Brakebusch, C. et al. Skin and hair follicle integrity is crucially dependent on beta 1 integrin expression on keratinocytes. EMBO J. 19, 3990-4003 (2000). (Pubitemid 30608538)
9. Faraldo, M. M., Deugnier, M. A., Lukashev, M., Thiery, J. P. & Glukhova, M. A. Perturbation of beta1-integrin function alters the development of murine mammary gland. EMBO J. 17, 2139-2147 (1998). (Pubitemid 28171899)
10. Folkman, J. & Moscona, A. Role of cell shape in growth control. Nature 273, 345-349 (1978). (Pubitemid 8344174)
11. Ruoslahti, E. & Reed, J. C. Anchorage dependence, integrins, and apoptosis. Cell 77, 477-478 (1994). (Pubitemid 24153987)
12. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
13. Bruix, J. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J. Hepatol. 57, 821-829 (2012).
14. Santoro, A. et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 14, 55-63 (2013).
15. Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J. & Bishop, J. M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153, 1023-1034 (2001).
16. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22 (2010).
17. Miranti, C. K. & Brugge, J. S. Sensing the environment: a historical perspective on integrin signal transduction. Nat. Cell Biol. 4, E83-E90 (2002). (Pubitemid 34308848)
18. Weis, S. M. & Cheresh, D. A. av integrins in angiogenesis and cancer. Cold Spring Harb. Perspect. Med. 1, a006478 (2011).
19. Aoudjit, F. & Vuori, K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20, 4995-5004 (2001). (Pubitemid 32769789)
20. Hodkinson, P. S. et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 13, 1776-1788 (2006). (Pubitemid 44390864)
21. Ferreira, M., Fujiwara, H., Morita, K. & Watt, F. M. An activating beta1 integrin mutation increases the conversion of benign to malignant skin tumors. Cancer Res. 69, 1334-1342 (2009).
22. Park, C. C. et al. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 66, 1526-1535 (2006). (Pubitemid 43259934)
23. Tward, A. D. et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc. Natl Acad. Sci. USA 104, 14771-14776 (2007). (Pubitemid 350003218)
24. Zeigerer, A. et al. Rab5 is necessary for the biogenesis of the endolysosomal system in vivo. Nature 485, 465-470 (2012).
25. Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864-1869 (2010).
26. Frank-Kamenetsky, M. et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA 105, 11915-11920 (2008).
27. Speicher, T. et al. Knockdown and knockout of b1-integrin in hepatocytes impairs liver regeneration through inhibition of growth factor signaling. Nat. Commun. doi:10. 1038/ncomms4862 (2014).
28. Akiyama, S. K. & Yamada, K. M. Biosynthesis and acquisition of biological activity of the fibronectin receptor. J. Biol. Chem. 262, 17536-17542 (1987). (Pubitemid 18032237)
29. Retta, S. F. et al. Cross talk between beta(1) and alpha(V) integrins: beta(1) affects beta(3) mRNA stability. Mol. Biol. Cell 12, 3126-3138 (2001).
30. Guan, K., Czyz, J., Fürst, D. O. & Wobus, A. M. Expression and cellular distribution of alpha(v)integrins in beta(1)integrin-deficient embryonic stem cell-derived cardiac cells. J. Mol. Cell. Cardiol. 33, 521-532 (2001). (Pubitemid 32539008)
31. Yu, W. et al. Beta1-integrin orients epithelial polarity via Rac1 and laminin. Mol. Biol. Cell 16, 433-445 (2005). (Pubitemid 40165545)
32. Godoy, P. et al. Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. Hepatology 49, 2031-2043 (2009).
33. Sheth, S. S. et al. Hepatocellular carcinoma in Txnip-deficient mice. Oncogene 25, 3528-3536 (2006). (Pubitemid 43901674)
34. Stauffer, J. K. et al. Coactivation of AKT and b-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res. 71, 2718-2727 (2011).
35. Yuneva, M. O. et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15, 157-170 (2012).
36. Chu, C. W. et al. Manifestations of hypercholesterolaemia, hypoglycaemia, erythrocytosis and hypercalcaemia in patients with hepatocellular carcinoma: report of two cases. J. Gastroenterol. Hepatol. 14, 807-810 (1999).
37. Wu, L., Fan, J. & Belasco, J. G. Importance of translation and nonnucleolytic ago proteins for on-target RNA interference. Curr. Biol. 18, 1327-1332 (2008).
38. Vickers, T. A. et al. Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 'Slicer' independent and can be mediated by Ago1. Nucleic Acids Res. 37, 6927-6941 (2009).
39. Giordano, S. et al. Biosynthesis of the protein encoded by the c-met protooncogene. Oncogene 4, 1383-1388 (1989). (Pubitemid 19273394)
40. Longati, P., Bardelli, A., Ponzetto, C., Naldini, L. & Comoglio, P. M. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 9, 49-57 (1994).
41. Schaller, M. D. et al. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol. Cell. Biol. 14, 1680-1688 (1994).
42. Reinehr, R., Gohlke, H., Sommerfeld, A., Vom Dahl, S. & HaÜssinger, D. Activation of integrins by urea in perfused rat liver. J. Biol. Chem. 285, 29348-29356 (2010).
43. HaÜssinger, D. et al. Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis. Gastroenterology 124, 1476-1487 (2003). (Pubitemid 36531820)
44. Malato, Y. et al. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J. Clin. Invest. 121, 4850-4860 (2011).
45. Magami, Y. et al. Cell proliferation and renewal of normal hepatocytes and bile duct cells in adult mouse liver. Liver 22, 419-425 (2002). (Pubitemid 35331403)
46. Blechacz, B. & Mishra, L. Hepatocellular carcinoma biology. Recent Results Cancer Res. 190, 1-20 (2013).
47. Doglioni, C. et al. Alterations of beta-catenin pathway in non-melanoma skin tumors: loss of alpha-ABC nuclear reactivity correlates with the presence of beta-catenin gene mutation. Am. J. Pathol. 163, 2277-2287 (2003). (Pubitemid 37466472)
48. Querbes, W. et al. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood 120, 1916-1922 (2012).
49. Trusolino, L., Bertotti, A. & Comoglio, P. M. A signaling adapter function for αbeta4 integrin in the control of HGF-dependent invasive growth. Cell 107, 643-654 (2001). (Pubitemid 34014865)
50. Mitra, A. K. et al. Ligand-independent activation of c-Met by fibronectin and a(5)b(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 30, 1566-1576 (2011).
51. Lee, Y. H. et al. Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene 30, 4175-4184 (2011).
52. Eke, I. et al. b1Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J. Clin. Invest. 122, 1529-1540 (2012).
53. Querbes, W. et al. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood 120, 1916-1922 (2012).
54. Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. 51, 8529-8533 (2012).
55. Zender, L. et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135, 852-864 (2008).
56. Perincheri, S., Dingle, R. W., Peterson, M. L. & Spear, B. T. Hereditary persistence of alpha-fetoprotein and H19 expression in liver of BALB/cJ mice is due to a retrovirus insertion in the Zhx2 gene. Proc. Natl Acad. Sci. U S A 102, 396-401 (2005). (Pubitemid 40116778)
57. Bissell, D. M., Hammaker, L. E. & Meyer, U. A. Parenchymal cells from adult rat liver in nonproliferating monolayer culture. I. Functional studies. J. Cell Biol. 59, 722-734 (1973).
58. Bucci, C. et al. Co-operative regulation of endocytosis by three Rab5 isoforms. FEBS Lett. 366, 65-71 (1995).